MiddleBrook Pharmaceuticals continues strategic review process

By Lisa Kerner

Charlotte, N.C., Feb. 14 - MiddleBrook Pharmaceuticals, Inc. has retained Morgan Stanley to assist the company and its co-adviser, Pacific Growth Equities, LLC, in the ongoing review of strategic alternatives.

The company is considering a range of alternatives including execution of MiddleBrook's operating plan, the sale of the company or its assets and collaborative agreements.

There can be no assurance any transaction will take place, the company said.

MiddleBrook does not intend to disclose developments in regards to the review process unless and until the evaluation of strategic alternatives has been completed, a company news release stated.

The Germantown, Md., pharmaceutical company specializes in anti-infective drug products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.